The highest efficacy dose from Phase 2, producing up to 24.2% average weight loss at 48 weeks
While GLP-1s can offer significant metabolic relief and even mood improvements in some users, doctors stress that they must be paired with healthy lifestyle habits and medical supervision to function optimally
[1] [2] It represents a novel class of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, making it the first dual incretin receptor agonist available in clinical practice
Before weight loss, some older adults already meet the clinical criteria for Sarcopenic Obesity, or Obesity co-incident with Sarcopenia
Biotin-conjugated anti-CD44 antibody-avidin binding system for the improvement of chondrocyte adhesion to scaffolds
If your current provider is unfamiliar with compounding, our guide on how to qualify for semaglutide and what to say when requesting GLP-1 options can help you navigate the conversation